It was reported on Wednesday that United States-based Additive Orthopaedics LLC has received approval from the United States Food and Drug Administration (FDA) for the Patient Specific Talus Spacer 3D-printed talus (ankle bone) implant for humanitarian use.
The product is a 3D printed implant that can be used in talus replacement surgery. The talus spacer is made individually for each patient, modelled from computed tomography imaging, and is fitted to a patient's specific anatomy. The Patient Specific Talus Spacer is claimed to be the first in the world and first-of-its-kind implant to replace the talus, the bone in the ankle joint that connects the leg and the foot, for the treatment of avascular necrosis (AVN) of the ankle joint, a serious and progressive condition that causes the death of bone tissue stemming from a lack of blood supply to the area.
The US FDA has reviewed data for the Patient Specific Talus Spacer via the humanitarian device exemption process.
AstraZeneca and FibroGen provide update on FDA review of roxadustat
Quidel awarded FDA's EUA for prescribed QuickVue At-Home COVID-19 Test with results in ten minutes
QureBio's Q-1802 receives US FDA Investigational New Drug application approval
J&J waiting regulatory approval for new plant to deliver high volumes of COVID-19 vaccines to US
Novavax expects its COVID-19 vaccine to be authorised in US by May 2021
Inovio completes Phase II enrolment for US trail of COVID-19 vaccine candidate
US FDA Accepts US Merck's Gefapixant New Drug Application for Review
McKesson Begins Distributing the Johnson and Johnson COVID-19 Vaccine